Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 7, 1998, Pages 571-580

  Gerotziafas, G T ^a,b   Bara, L ^b   Bloch, M F ^b   Makris, P E ^c   Samama, M M ^a  

^a HÔTEL DIEU   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Factor VII; Factor VII activation; Factor VIIa; Hirudin; LMWH; Pentasaccharide; Prothrombin activation; UFH

Indexed keywords

BLOOD CLOTTING FACTOR 7A; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PROTHROMBIN;

ARTICLE; BLOOD CLOTTING; CATALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HEMOSTASIS; HUMAN; PLASMA; PRIORITY JOURNAL;

EID: 0031797682     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199810000-00002     Document Type: Article

References (36)

1. Rao LVM, Rapaport SI. Activation of factor VII bound to tissue factor: a key step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6686-6691.
2. Nemerson Y. The tissue factor pathway of blood coagulation. In: Colman RW, Hirsh J, Marder V, Salzman EW, (editors): Haemostasis and thrombosis. Basic principles and clinical practice. Third edition. Philadelphia, PA: J. B. Lippincott Company; 1994. pp. 81-92.
3. Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, et al. Factor IXa-Factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood 1992; 79: 2039-2047.
4. Gemmell CH, Turitto VT, Nemerson Y. Factors affecting the interaction of tissue factor/factor VII with factor X in a heterogenous tubular reactor. Thromb Haemost 1991; 65: 139-143.
5. Bauer KA, Kass BL, Ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-736.
6. Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad USA 1977; 74: 5260-5264.
7. Morissey JH, Macik BG, Neuenschwande PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
8. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-28.
9. Josso F, Prou-Wartelle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. Thromb Diath Haemorrh 1965; 17: 35-44.
10. Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII. The role of a bifunctional coagulation cofactor. Thromb Res 1985; 40: 351-358.
11. Seligsohn U, Østerud B, Brown SF, Griffin JH. Activation of human factor VII in plasma and in purified systems. J Clin Invest 1979; 64: 1056-1065.
12. Eichinger S, Mannucci PM, Tradati F, Arbini AA, Rosenberg RD. Determinants of plasma factor VIIa levels in humans. Blood 1995; 86: 3021-3025.
13. Radcliffe R, Nemerson Y. The activation of factor VII by activated factor X and thrombin. Isolation of a single chain form of factor VII. J Biol Chem 1975; 250: 388-395.
14. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
15. Lindhout T, Franssen J, Willems G. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 910-915.
16. Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546.
17. Hemker HC. The mode of action of heparin in plasma. In: Verstraete M, Vermylen J, Lijnen HR, Arnout J (editors): Thrombosis and haemostasis. Leuven: International Society on Thrombosis and Haemostasis and Leuven University Press; 1987. pp. 17-36.
18. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994; 24: 105-117.
19. Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23: 103-106.
20. Valentin S, Ostergaard P, Kristensen H, Nordfang O. Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays. Blood Coag Fibrinol 1991; 2: 629-635.
21. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordøy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 1996; 76: 703-709.
22. Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM. Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood. Thromb Res 1996; 81: 491-496.
23. Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM. Treatment with LMWHs inhibits factor VII activation. Preliminary results [abstract]. Haemostasis 1994; 24: 245.
24. Rao VM, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/ heparin inhibition of factor VIIa. Blood 1993; 81: 2600-2607.
25. Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost 1996; 76: 5-8.
26. Hubbard AR, Barrowcliffe TW. Measurement of activity factor VII using soluble mutant tissue factor proposal for standardisation. Thromb Haemost 1994; 72: 644-650.
27. Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM. Inhibition of FVIIa generation by UFH, LMWH and synthetic pentasaccharide. Mechanism of action. Preliminary results [abstract]. Thromb Haemost 1997; 8 (suppl): 28.
28. Beguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61: 379-401.
29. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499.
30. Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-468.
31. Lormeau JC, Herault JP. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic pentasaccharide. Thromb Haemost 1993; 69: 152-156.
32. Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988; 51: 23-33.
33. Bendetowitcz AV, Bara L, Samama MM. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. Thromb Res 1990; 58: 445-454.
34. Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin activation in whole blood during coagulation and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-452.
35. Walenga JM. Factor Xa inhibition in mediating antithrombotic actions: application of a synthetic heparin pentasaccharides. Doctoral thesis; 1987. Université Pierre et Marie Curie, Paris IV, Paris, France.
36. Ofosu FA, Leclerc J, Delorme F, Craven S, Shafai S, Frewin L, et al. The low molecular weight heparin enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery. Br J Haematol 1992; 82: 391-399.